Indium In 111 Ibritumomab Tiuxetan Injection
» Ibritumomab Tiuxetan is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)ethyl)glycine. This chelate provides a high-affinity, conformationally restricted chelation site for Yttrium-90 and Indium-111. The approximate molecular weight of Ibritumomab Tiuxetan is 148 kD.
Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Indium In 111 Ibritumomab Tiuxetan Injection is a sterile, nonpyrogenic preparation of the immunoconjugate of ibritumomab and tiuxetan that is labeled with 111In and is suitable for intravenous administration. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of 111In as the ibritumomab complex, expressed in megabecquerels (or millicuries) per mL at the time indicated in the labeling. It may contain buffers and stabilizers. It contains no antimicrobial agents. Other chemical forms of radioactivity do not exceed 5 percent of the total radioactivity. The immunoreactive fraction, as determined by a validated method, is not less than 90 percent.
Packaging and storage Preserve in single-dose containers, and store in a refrigerator for not more than 12 hours. [noteTranslucent protein particles may develop, which are removed by filtration prior to administration using a 0.22 micron low-protein-binding filter.]
Labeling Label it to include the following in addition to the information specified for Labeling under Injections 1: the time and date of calibration; the amount of 111In Ibritumomab Tiuxetan as total MBq (or mCi) and concentration of MBq (or mCi) per mL at the time of calibration; the expiration date and time; the storage temperature; and the statement, CautionRadioactive Material. The labeling indicates that, in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 111In is 67.3 hours.
Bacterial endotoxins 85 The limit of endotoxin content is not more than 175/V USP Endotoxin Units per mL of the Injection, when compared with the USP Endotoxin RS, in which V is the maximum recommended total dose, in mL, at the expiration date or time.
pH 791: between 5.5 and 7.5.
Absorbent: 1- × 8-cm instant silica gel strip.
Test solution: the Injection.
Application volume: 10 µL.
Developing solvent system: 0.9 % sodium chloride solution.
Procedure Proceed as directed for Thin-Layer Chromatography under Chromatography 621 by ascending chromatography. Determine the distribution of radioactivity on the chromatogram by scanning with a suitable collimated radiochromatogram strip scanner, and determine the percentage of radiochemical purity of the test specimen. Not less than 95% of the In 111 activity is present as a band between the RF values of 0 and 0.1.
Other requirements It meets the requirements for Radionuclide identification and Radionuclidic purity under Indium In 111 Chloride Solution. It meets also the requirements under Injections 1, except that the radioactive component may be distributed or dispensed prior to completion of the test for Sterility, the latter test being started on the date of manufacture.
Assay for radioactivity 821 Using a suitable counting assembly (see Selection of a Counting Assembly), determine the total radioactivity, in MBq (or µCi) of the unshielded Injection by use of a calibrated system.
Auxiliary Information Please check for your question in the FAQs before contacting USP.
USP32NF27 Page 2628